Table 1 New I patients switching to O, by sex, age group and year of starting I (percent and overall proportion)

From: Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis

 

New patients in 2002

New patients in 2003

Age group

Male (%)

Female (%)

Male (%)

Female (%)

<50

58

55

55

48

59–59

52

53

52

58

60–69

43

35%

45

45

70–79

44

33

38

26

⩾80

27

29

17

100

Overall

45 (344/768)

 

45 (234/525)

 
  1. I, irinotecan; O, oxaliplatin.
Back to article page